US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

48.06

+0.57331.21%

Post-market: 47.11-0.9528-1.98%19:30 EDT

Volume:5K

Turnover:221.35K

Market Cap:132.51M

PE:- -

High:48.19

Open:48.00

Low:47.87

Close:47.49

52wk High:48.78

52wk Low:27.34

Shares:2.76M

Float Shares:2.76M

Volume Ratio:1.31

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino

Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors

Spyre Therapeutics Won't Prioritize Rheumatoid Arthritis Monotherapy After Trial

Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-Study of the Skyway Phase 2 Trial of Spy072

THOMSON REUTERS

Spyre Therapeutics - Spy072 Well Tolerated with Adverse Event Rates Comparable to Placebo

THOMSON REUTERS

Spyre Therapeutics Inc: Spy072 in Combination with Il17-a/F in Hidradenitis Suppurativa (Hs) in Late 2027 or Early 2028

THOMSON REUTERS

Spyre Therapeutics - Topline Data for Spy072 in Psa and Axspa Expected Q4 2026

THOMSON REUTERS

Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis

THOMSON REUTERS

Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints

THOMSON REUTERS

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Circio bolsters board as it advances circular RNA gene therapy platform

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares

Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall

MT Newswires Live

Guardant Health to appeal federal district court judgment in TwinStrand case

Guardant Health, Inc.: Remains Confident That it Did not Infringe Asserted Patents

THOMSON REUTERS

Guardant Health, - Current Guardant Reveal and Shield Products Excluded from Final Court Order

THOMSON REUTERS

Guardant Health to Appeal Federal District Court Judgment

THOMSON REUTERS

U.S. Court Orders Guardant to Pay $245 Million in DNA Sequencing Patent Dispute

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LFSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":48.0628,"timestamp":1787688000000,"preClose":47.4895,"halted":0,"volume":4612,"hourTrading":{"tag":"盘后","latestPrice":47.11,"preClose":48.0628,"latestTime":"19:30 EDT","volume":194,"amount":9205.2812,"timestamp":1787700602165,"change":-0.9528,"changeRate":-0.019824,"amplitude":0.019142},"delay":0,"changeRate":0.012072142263026633,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Closed","change":0.5733,"latestTime":"08-25 16:00:00 EDT","open":48,"high":48.19,"low":47.87,"amount":221346.80604,"amplitude":0.006738,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":47.4895,"sharesOutstanding":2657035,"nav":47.45,"aum":130821310.75,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":47.11,"preClose":48.0628,"latestTime":"19:30 EDT","volume":194,"amount":9205.2812,"timestamp":1787700602165,"change":-0.9528,"changeRate":-0.019824,"amplitude":0.019142},"volumeRatio":1.311494},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.311494,"shares":2757035,"dividePrice":0,"high":48.19,"amplitude":0.006738,"preClose":47.4895,"low":47.87,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":48.0628,"eps":0,"divideRate":0,"volume":4612,"delay":0,"ttmEps":0,"open":48,"prevYearClose":36.6147,"prevWeekClose":47.7953,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.489,"twentyDayClose":45.3952,"sixtyDayClose":39.3901},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662768622","title":"Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768622","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662768622?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:05","pubTimestamp":1787699100,"startTime":"0","endTime":"0","summary":"Intuit projected that sales growth would slow in the year ahead, weighed down by expected declines in the company's desktop business. The company may also accept short-term trade-offs in its business as it looks to boost TurboTax customers, its CFO told The Wall Street Journal. Shares fell 9.8% to $322.57 in after-hours trading on Tuesday.Spyre Therapeutics said it will not prioritize developing one of its drug candidates as a monotherapy for rheumatoid arthritis after results from a trial missed its internal targets. The stock slid 11% to $95.09 after the bell.Zoom Communications issued guidance for third-quarter adjusted earnings per share that missed Wall Street expectations. Shares were down 3.9% at $97.00.NCino projected third-quarter revenue in a range with a midpoint below analyst expectations. The stock was down 5.6% at $19.65.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","LU0861579265.USD","LU1043141396.HKD","LU1803068979.SGD","LU1861558580.USD","LU1823568750.SGD","BK4613","LU0889565833.HKD","BK4548","LU0266013472.USD","LU0661504455.SGD","LU1934455863.HKD","BK4554","LU1674673428.USD","LU2065170008.USD","LU0511384066.AUD","BK4528","IE00B19Z8W00.USD","LU1674673691.USD","BK4535","BK4023","LU2089283258.USD","LFSC","LU1815333072.USD","LU1804176565.USD","NCNO","LU2065171402.SGD","LU0738911758.USD","LU1934455194.USD","LU0289961442.SGD","LU0061474960.USD","LU0965508806.USD","IE00BQXX3C00.GBP","LU1861559042.SGD","LU1037948897.HKD","BK4581","SG9999001424.SGD","BK4139","LU1366333091.USD","LU0823434583.USD","LU0097036916.USD","LU2095319765.USD","LU0640476718.USD","SG9999002232.USD","BK4567","LU0426417589.USD","BK4525","BK4534","LU1235294995.USD","LU0965509283.SGD","LU0965509010.AUD","LU2065171311.SGD","LU0011850046.USD","LU0957791311.USD","SG9999002224.SGD","SYRE","ZM","BK4505","LU1121112475.USD","LU0158827948.USD","IE00BQXX3D17.EUR","LU1043141123.HKD","LU0109392836.USD","BK4585","LU0689626769.HKD","IE0009356076.USD","INTU","LU0426412945.USD","LU0124676726.USD","LU1046421795.USD","IE00B19Z8X17.USD","LU0289739343.SGD","LU0082616367.USD","LU2063271972.USD","BK4588","LU1037948541.HKD","BK4532","LU0157215616.USD","LU1934455277.USD","LU2023251221.USD","BK4608","BK4551","LU0342679015.USD","IE00B19Z9505.USD","LU0719512351.SGD","LU1280957306.USD","LU0949170772.SGD","BK4533","LU0345774391.USD","LU1236620750.USD","LU1778281490.HKD","IE00B5949003.HKD","LU1236620834.HKD","LU2265009873.SGD","LU2089284900.SGD","LU2210150020.SGD","LU0994945656.USD","LU2065169927.USD","LU2210149790.SGD","LU0965509101.SGD","LU0345774631.USD","IE00BQXX3F31.USD","GB00BDT5M118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776851","title":"Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662776851?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:51","pubTimestamp":1787698276,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics ($SYRE) fell as much as 14% in after‑hours trading on Tuesday after the company said it will stop developing its rheumatoid arth...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/spyre-therapeutics-stock-syre-tumbles-14-in-after-hours-heres-what-spooked-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/spyre-therapeutics-stock-syre-tumbles-14-in-after-hours-heres-what-spooked-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","ISBC","BK4139","BK4211","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662675221","title":"Spyre Therapeutics Won't Prioritize Rheumatoid Arthritis Monotherapy After Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662675221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662675221?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:00","pubTimestamp":1787691600,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics will not prioritize the use of its SPY072 drug candidate as a monotherapy to treat rheumatoid arthritis, saying that results from a phase 2 trial did not meet the company's threshold.Shares of the biotechnology company fell on the news, losing 13% in after-hours trading to $93.50.A substudy of the drug to treat rheumatoid arthritis, part of a broader phase 2 study focusing on rheumatic diseases, showed that high and low doses both had statistically significant benefits over a placebo on certain endpoints, Spyre said. The low dose demonstrated a statistically significant benefit on the study's primary endpoint, the company added.But the magnitude of the results missed the company's targets, it said.\"The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company's internal bar to prioritize advancement of SPY072 in RA,\" the company said. SPY072 is designed to inhi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SYRE","BK4007","BK4139","LENZ","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754700","title":"Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754700?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:05","pubTimestamp":1787688312,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-results-from-ra-sub-study-of-skyway-basket-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-results-from-ra-sub-study-of-skyway-basket-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RA","SYRE","LENZ","LFSC","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662981754","title":"Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-Study of the Skyway Phase 2 Trial of Spy072","url":"https://stock-news.laohu8.com/highlight/detail?id=2662981754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662981754?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754989","title":"Spyre Therapeutics - Spy072 Well Tolerated with Adverse Event Rates Comparable to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754989?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754982","title":"Spyre Therapeutics Inc: Spy072 in Combination with Il17-a/F in Hidradenitis Suppurativa (Hs) in Late 2027 or Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754982?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662549867","title":"Spyre Therapeutics - Topline Data for Spy072 in Psa and Axspa Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662549867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662549867?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662549807","title":"Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662549807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662549807?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662475498","title":"Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662475498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662475498?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175441","title":"Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175441?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":"Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350866/0/en/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-the-skyway-phase-2-trial-of-spy072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RA","LENZ","BK4007","BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759663","title":"Circio bolsters board as it advances circular RNA gene therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759663?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:07","pubTimestamp":1787677640,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA has strengthened its board of directors as it enters a new development p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","SYNB","TBXU","IBB","FBT","GNOM","IE0009354923.USD","CNCR","BK4139","BK4505","BK4585","IBBQ","RNA","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","PINK","BK4139","BMED","IEIH","BK4588","BK4526","MEDI","TBXU","NVIB","TECB","XLVX","MRNX","IDNA","PSCH","GDOC","BK4585","GNMX","LFSC","BBP","RSPH","MRNY","ONC","IBB","LABU","SYNB","FRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020952","title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020952","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662020952?lang=en_us&edition=fundamental","pubTime":"2026-08-25 05:22","pubTimestamp":1787606549,"startTime":"0","endTime":"0","summary":"Guardant Health Co-CEO AmirAli Talasaz disposes of USD 6.35 million in common sharesGuardant Health Co-CEO AmirAli Talasaz sold 37,500 common shares on Aug. 21, 2026 through the Talasaz Family Foundat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9NSL6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4588","EKG","LFSC","PTH","GH","GNOM","HELX","LU0889565916.HKD","GNMX","BK4535","FFOX","LU0109394709.USD","LU0320765992.SGD","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205974","title":"Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205974?lang=en_us&edition=fundamental","pubTime":"2026-08-25 03:41","pubTimestamp":1787600471,"startTime":"0","endTime":"0","summary":"Guardant Health  said Monday it will appeal the final judgment of a Delaware district court related to a patent infringement dispute with TwinStrand Biosciences and University of Washington.The company said execution of the court's final decision and collection of potential royalties are on hold, pending the appeal.The potential royalties do not apply to the company's current versions of Guardant Reveal and Shield, which feature updated technology. Additionally, the company has made design improvements to Guardant360 that would exclude the impact of potential ongoing royalties.The patents have also been preliminarily invalidated in separate challenges before the US Patent and Trademark Office, the company added.Shares fell around 3.5% in late afternoon trading.Price: 164.62, Change: -6.07, Percent Change: -3.56","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","GNOM","HELX","BK4588","LFSC","BK4535","GDOC","EKG","GNMX","PTH","LU0109394709.USD","BK4585","BK4196","GH","FFOX","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662030912","title":"Guardant Health to appeal federal district court judgment in TwinStrand case","url":"https://stock-news.laohu8.com/highlight/detail?id=2662030912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662030912?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:55","pubTimestamp":1787597714,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-to-appeal-federal-district-court-judgment-in-twinstrand-case-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-to-appeal-federal-district-court-judgment-in-twinstrand-case-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FFOX","LU0889565916.HKD","PTH","EKG","BK4551","LFSC","BK4535","LU0320765992.SGD","GDOC","GH","BK4196","GNOM","LU0109394709.USD","BK4585","HELX","GNMX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203463","title":"Guardant Health, Inc.: Remains Confident That it Did not Infringe Asserted Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203463?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:44","pubTimestamp":1787597047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0L4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0320765992.SGD","HELX","BK4588","GNOM","LU0889565916.HKD","GH","GNMX","FFOX","EKG","PTH","LFSC","BK4551","BK4535","BK4585","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203434","title":"Guardant Health, - Current Guardant Reveal and Shield Products Excluded from Final Court Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203434","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203434?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:44","pubTimestamp":1787597047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0L4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNMX","LFSC","BK4588","BK4196","BK4585","BK4551","EKG","FFOX","GDOC","GH","LU0889565916.HKD","GNOM","PTH","HELX","LU0109394709.USD","LU0320765992.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034312","title":"Guardant Health to Appeal Federal District Court Judgment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662034312?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:44","pubTimestamp":1787597047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4196","GH","EKG","LU0320765992.SGD","GNOM","FFOX","LU0109394709.USD","GNMX","GDOC","LFSC","BK4551","BK4535","HELX","PTH","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662520885","title":"U.S. Court Orders Guardant to Pay $245 Million in DNA Sequencing Patent Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2662520885","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662520885?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:55","pubTimestamp":1787590534,"startTime":"0","endTime":"0","summary":"UPDATE 2-U.S. court orders Guardant to pay $245 million in DNA sequencing patent disputeAug 24 (Reuters)-A U.S. court has ordered Guardant Health to pay more than $245.2 million to TwinStrand Bioscien","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4N44L18D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","HELX","BK4588","BK4535","LU0109394709.USD","LU0053671581.USD","GDOC","BK4551","BK4585","SAIA","EKG","BK4022","LU2065731478.USD","FFOX","LFSC","PTH","BK4232","BK4196","GNOM","LU0320765992.SGD","GH","GNMX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":198,"code":"91000000","status":"200"}]}}